| Literature DB >> 30259848 |
Kimberly A Wong1, Runalia Bahar1, Chung H Liu2, Christopher L Bowlus3.
Abstract
Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.Entities:
Keywords: Autoimmune liver disease; Bile acids; Farnesoid X receptor; Therapy
Mesh:
Substances:
Year: 2018 PMID: 30259848 DOI: 10.1016/j.cld.2018.03.003
Source DB: PubMed Journal: Clin Liver Dis ISSN: 1089-3261 Impact factor: 6.126